Advertisement

Leiomyosarcoma

Current Clinical Management and Future Horizons

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gronchi A.
        • Strauss D.C.
        • Miceli R.
        • et al.
        Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS working group.
        Ann Surg. 2016; 263: 1002-1009
        • Serrano C.
        • George S.
        Leiomyosarcoma.
        Hematol Oncol Clin North Am. 2013; 27: 957-974
        • George S.
        • Serrano C.
        • Hensley M.L.
        • et al.
        Soft tissue and uterine leiomyosarcoma.
        J Clin Oncol. 2018; 36: 144-150
        • Hashimoto H.
        • Tsuneyoshi M.
        • Enjoji M.
        Malignant smooth muscle tumors of the retroperitoneum and mesentery: a clinicopathologic analysis of 44 cases.
        J Surg Oncol. 1985; 28: 177-186
      1. Cancer IAfRo, editor. WHO classification of tumours of soft tissue and bone. 5 edition. Lyon (France)2020.

        • Gustafson P.
        Soft tissue sarcoma. Epidemiology and prognosis in 508 patients.
        Acta Orthop Scand Suppl. 1994; 259: 1-31
        • Amant F.
        • Coosemans A.
        • Debiec-Rychter M.
        • et al.
        Clinical management of uterine sarcomas.
        Lancet Oncol. 2009; 10: 1188-1198
        • Katz S.C.
        • DeMatteo R.P.
        Gastrointestinal stromal tumors and leiomyosarcomas.
        J Surg Oncol. 2008; 97: 350-359
        • Svarvar C.
        • Bohling T.
        • Berlin O.
        • et al.
        Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group.
        Cancer. 2007; 109: 282-291
        • Berlin Ö.
        • Stener B.
        • Kindblom L.-G.
        • et al.
        Leiomyosarcomas of venous origin in the extremities. A correlated clinical, roentgenologic, and morphologic study with diagnostic and surgical implications.
        Cancer. 1984; 54: 2147-2159
        • Clary B.M.
        • DeMatteo R.P.
        • Lewis J.J.
        • et al.
        Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison.
        Ann Surg Oncol. 2001; 8: 290-299
        • Gladdy R.A.
        • Qin L.X.
        • Moraco N.
        • et al.
        Predictors of survival and recurrence in primary leiomyosarcoma.
        Ann Surg Oncol. 2013; 20: 1851-1857
        • Fong Y.
        • Coit D.G.
        • Woodruff J.M.
        • et al.
        Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients.
        Ann Surg. 1993; 217: 72-77
        • Kleinerman R.A.
        • Schonfeld S.J.
        • Sigel B.S.
        • et al.
        Bone and soft-tissue sarcoma risk in long-term survivors of hereditary retinoblastoma treated with radiation.
        J Clin Oncol. 2019; 37: 3436-3445
        • Trojani M.
        • Contesso G.
        • Coindre J.M.
        • et al.
        Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system.
        Int J Cancer. 1984; 33: 37-42
        • Anderson N.D.
        • Babichev Y.
        • Fuligni F.
        • et al.
        Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival.
        Nat Commun. 2021; 12: 4496
        • Chudasama P.
        • Mughal S.S.
        • Sanders M.A.
        • et al.
        Integrative genomic and transcriptomic analysis of leiomyosarcoma.
        Nat Commun. 2018; 9: 144
        • Cancer Genome Atlas Research Network
        Comprehensive and integrated genomic characterization of adult soft tissue sarcomas.
        Cell. 2017; 171: 950-965 e28
        • Beck A.H.
        • Lee C.H.
        • Witten D.M.
        • et al.
        Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.
        Oncogene. 2010; 29: 845-854
        • Hemming M.L.
        • Fan C.
        • Raut C.P.
        • et al.
        Oncogenic gene-expression programs in leiomyosarcoma and characterization of conventional, inflammatory, and uterogenic subtypes.
        Mol Cancer Res. 2020; 18: 1302-1314
        • Crago A.M.
        • Brennan M.F.
        Principles in management of soft tissue sarcoma.
        Adv Surg. 2015; 49: 107-122
        • O'Sullivan P.J.
        • Harris A.C.
        • Munk P.L.
        Radiological imaging features of non-uterine leiomyosarcoma.
        Br J Radiol. 2008; 81: 73-81
        • Benz M.R.
        • Dry S.M.
        • Eilber F.C.
        • et al.
        Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET.
        J Nucl Med. 2010; 51: 1174-1181
        • Van Houdt W.J.
        • Schrijver A.M.
        • Cohen-Hallaleh R.B.
        • et al.
        Needle tract seeding following core biopsies in retroperitoneal sarcoma.
        Eur J Surg Oncol. 2017; 43: 1740-1745
        • Berger-Richardson D.
        • Burtenshaw S.M.
        • Ibrahim A.M.
        • et al.
        Early and late complications of percutaneous core needle biopsy of retroperitoneal tumors at two tertiary sarcoma centers.
        Ann Surg Oncol. 2019; 26: 4692-4698
        • Swallow C.J.
        • Strauss D.C.
        • Bonvalot S.
        • et al.
        Management of primary retroperitoneal sarcoma (RPS) in the adult: an updated consensus approach from the Transatlantic Australasian RPS Working Group.
        Ann Surg Oncol. 2021; 28: 7873-7888
        • Tseng W.W.
        • Barretta F.
        • Conti L.
        • et al.
        Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: a multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group.
        Cancer. 2021; 127: 729-738
        • D'Ambrosio L.
        • Touati N.
        • Blay J.Y.
        • et al.
        Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
        Cancer. 2020; 126: 2637-2647
        • Bonvalot S.
        • Gronchi A.
        • Le Péchoux C.
        • et al.
        Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2020; 21: 1366-1377
        • Fiore M.
        • Colombo C.
        • Locati P.
        • et al.
        Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava.
        Ann Surg Oncol. 2012; 19: 511-518
        • Bonvalot S.
        • Miceli R.
        • Berselli M.
        • et al.
        Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control.
        Ann Surg Oncol. 2010; 17: 1507-1514
        • Gronchi A.
        • Lo Vullo S.
        • Fiore M.
        • et al.
        Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients.
        J Clin Oncol. 2009; 27: 24-30
        • MacNeill A.J.
        • Gronchi A.
        • Miceli R.
        • et al.
        Postoperative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the Transatlantic RPS Working Group.
        Ann Surg. 2018; 267: 959-964
        • Ferraris M.
        • Callegaro D.
        • Barretta F.
        • et al.
        Outcome of iliocaval resection and reconstruction for retroperitoneal sarcoma.
        J Vasc Surg Venous Lymphat Disord. 2019; 7: 547-556
        • Grilley-Olson J.E.
        • Webber N.P.
        • Demos D.S.
        • et al.
        Multidisciplinary management of oligometastatic soft tissue sarcoma.
        Am Soc Clin Oncol Educ Book. 2018; 38: 939-948
        • Wigge S.
        • Heissner K.
        • Steger V.
        • et al.
        Impact of surgery in patients with metastatic soft tissue sarcoma: a monocentric retrospective analysis.
        J Surg Oncol. 2018; 118: 167-176
        • Tan M.C.
        • Brennan M.F.
        • Kuk D.
        • et al.
        Histology-based classification predicts pattern of recurrence and improves risk stratification in primary retroperitoneal sarcoma.
        Ann Surg. 2016; 263: 593-600
        • Mbatani N.
        • Olawaiye A.B.
        • Prat J.
        Uterine sarcomas.
        Int J Gynaecol Obstet. 2018; 143: 51-58
        • Ricci S.
        • Stone R.L.
        • Fader A.N.
        Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
        Gynecol Oncol. 2017; 145: 208-216
      2. Martee L Hensley MML. Treatment and Prognosis of Uterine Leiomyosarcoma. UptoDate [Internet]. 2021.

      3. Stewart EA. Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas. UptoDate [Internet]. 2021.

        • Hinchcliff E.M.
        • Esselen K.M.
        • Watkins J.C.
        • et al.
        The role of endometrial biopsy in the preoperative detection of uterine leiomyosarcoma.
        J Minim Invasive Gynecol. 2016; 23: 567-572
        • Di Cello A.
        • Borelli M.
        • Marra M.L.
        • et al.
        A more accurate method to interpret lactate dehydrogenase (LDH) isoenzymes' results in patients with uterine masses.
        Eur J Obstet Gynecol Reprod Biol. 2019; 236: 143-147
      4. National Comprehensive Cancer Network. Uterine Neoplasms. 2021. In: NCCN Clinical Practice Guidelines in Oncology [Internet].

        • Bogani G.
        • Cliby W.A.
        • Aletti G.D.
        Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis.
        Gynecol Oncol. 2015; 137: 167-172
        • Toubia T.
        • Moulder J.K.
        • Schiff L.D.
        • et al.
        Peritoneal washings after power morcellation in laparoscopic myomectomy: a pilot study.
        J Minim Invasive Gynecol. 2016; 23: 578-581
        • Kim S.I.
        • Choi C.H.
        • Kim K.
        • et al.
        Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: a Korean multicenter study.
        J Obstet Gynaecol Res. 2020; 46: 337-346
        • Seagle B.L.
        • Sobecki-Rausch J.
        • Strohl A.E.
        • et al.
        Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study.
        Gynecol Oncol. 2017; 145: 61-70
        • Cybulska P.
        • Sioulas V.
        • Orfanelli T.
        • et al.
        Secondary surgical resection for patients with recurrent uterine leiomyosarcoma.
        Gynecol Oncol. 2019; 154: 333-337
        • Matsuzaki S.
        • Matsuzaki S.
        • Chang E.J.
        • et al.
        Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma: a systematic review of literature.
        Gynecol Oncol. 2021; 161: 70-77
        • Gronchi A.
        • Maki R.G.
        • Jones R.L.
        Treatment of soft tissue sarcoma: a focus on earlier stages.
        Future Oncol. 2017; 13: 13-21
        • Woll P.J.
        • Reichardt P.
        • Le Cesne A.
        • et al.
        Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
        Lancet Oncol. 2012; 13: 1045-1054
        • Frustaci S.
        • Gherlinzoni F.
        • De Paoli A.
        • et al.
        Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.
        J Clin Oncol. 2001; 19: 1238-1247
      5. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data.
        Lancet. 1997; 350: 1647-1654
        • Pervaiz N.
        • Colterjohn N.
        • Farrokhyar F.
        • et al.
        A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.
        Cancer. 2008; 113: 573-581
        • Le Cesne A.
        • Ouali M.
        • Leahy M.G.
        • et al.
        Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.
        Ann Oncol. 2014; 25: 2425-2432
        • von Mehren M.
        • Kane J.M.
        • Bui M.M.
        • et al.
        NCCN guidelines insights: soft tissue sarcoma, version 1.2021.
        J Natl Compr Canc Netw. 2020; 18: 1604-1612
        • Van Glabbeke M.
        • van Oosterom A.T.
        • Oosterhuis J.W.
        • et al.
        Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
        J Clin Oncol. 1999; 17: 150-157
        • Savina M.
        • Le Cesne A.
        • Blay J.Y.
        • et al.
        Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study.
        BMC Med. 2017; 15: 78
        • Judson I.
        • Verweij J.
        • Gelderblom H.
        • et al.
        Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
        Lancet Oncol. 2014; 15: 415-423
        • Tap W.D.
        • Wagner A.J.
        • Schoffski P.
        • et al.
        Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial.
        JAMA. 2020; 323: 1266-1276
        • Seddon B.
        • Strauss S.J.
        • Whelan J.
        • et al.
        Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
        Lancet Oncol. 2017; 18: 1397-1410
        • Tap W.D.
        • Papai Z.
        • Van Tine B.A.
        • et al.
        Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
        Lancet Oncol. 2017; 18: 1089-1103
        • Hensley M.L.
        • Blessing J.A.
        • Degeest K.
        • et al.
        Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
        Gynecol Oncol. 2008; 109: 323-328
        • Pautier P.
        • Floquet A.
        • Penel N.
        • et al.
        Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).
        Oncologist. 2012; 17: 1213-1220
        • Demetri G.D.
        • von Mehren M.
        • Jones R.L.
        • et al.
        Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial.
        J Clin Oncol. 2016; 34: 786-793
        • Patel S.
        • von Mehren M.
        • Reed D.R.
        • et al.
        Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
        Cancer. 2019; 125: 2610-2620
        • Schöffski P.
        • Chawla S.
        • Maki R.G.
        • et al.
        Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
        Lancet. 2016; 387: 1629-1637
        • Maki R.G.
        • Wathen J.K.
        • Patel S.R.
        • et al.
        Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
        J Clin Oncol. 2007; 25: 2755-2763
        • Sutton G.
        • Blessing J.
        • Hanjani P.
        • et al.
        Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
        Gynecol Oncol. 2005; 96: 749-752
        • van der Graaf W.T.A.
        • Blay J.-Y.
        • Chawla S.P.
        • et al.
        Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
        The Lancet. 2012; 379: 1879-1886
        • Benson C.
        • Ray-Coquard I.
        • Sleijfer S.
        • et al.
        Outcome of uterine sarcoma patients treated with pazopanib: a retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
        Gynecol Oncol. 2016; 142: 89-94
        • George S.
        • Feng Y.
        • Manola J.
        • et al.
        Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
        Cancer. 2014; 120: 738-743
        • O'Cearbhaill R.
        • Zhou Q.
        • Iasonos A.
        • et al.
        Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.
        Gynecol Oncol. 2010; 116: 424-429
        • Ben-Ami E.
        • Barysauskas C.M.
        • Solomon S.
        • et al.
        Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study.
        Cancer. 2017; 123: 3285-3290
        • Tawbi H.A.
        • Burgess M.
        • Bolejack V.
        • et al.
        Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
        Lancet Oncol. 2017; 18: 1493-1501
        • Monga V.
        • Skubitz K.M.
        • Maliske S.
        • et al.
        A retrospective analysis of the efficacy of immunotherapy in metastatic soft-tissue sarcomas.
        Cancers (Basel). 2020; 12
        • D'Angelo S.P.
        • Mahoney M.R.
        • Van Tine B.A.
        • et al.
        Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
        Lancet Oncol. 2018; 19: 416-426
        • Petitprez F.
        • de Reynies A.
        • Keung E.Z.
        • et al.
        B cells are associated with survival and immunotherapy response in sarcoma.
        Nature. 2020; 577: 556-560
        • Danaher P.
        • Warren S.
        • Lu R.
        • et al.
        Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).
        J Immunother Cancer. 2018; 6: 63
        • Kasper B.
        • Achee A.
        • Schuster K.
        • et al.
        Unmet medical needs and future perspectives for leiomyosarcoma patients-a position paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN).
        Cancers (Basel). 2021; 13
        • Przybyl J.
        • Spans L.
        • Lum D.A.
        • et al.
        Detection of circulating tumor DNA in patients with uterine leiomyomas.
        JCO Precis Oncol. 2019; 3
        • Hemming M.L.
        • Klega K.S.
        • Rhoades J.
        • et al.
        Detection of circulating tumor DNA in patients with leiomyosarcoma with progressive disease.
        JCO Precis Oncol. 2019; 2019
        • Przybyl J.
        • Chabon J.J.
        • Spans L.
        • et al.
        Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma.
        Clin Cancer Res. 2018; 24: 2688-2699
        • Oza J.
        • Doshi S.D.
        • Hao L.
        • et al.
        Homologous recombination repair deficiency as a therapeutic target in sarcoma.
        Semin Oncol. 2020; 47: 380-389